TG Therapeutics, Inc.
NASDAQTG Therapeutics enters the second half of 2026 with a striking contradiction at its core — short sellers are rebuilding positions into a stock that has just posted a 45% monthly gain, yet the borrow market remains remarkably relaxed. Short interest at 20.2% of the free float is genuinely elevated, and it has grown. Shorts added around 1.6 million shares over the past month, lifting…
Snapshot as of 5 Aug 2026
TG Therapeutics enters the second half of 2026 with a striking contradiction at its core — short sellers are rebuilding positions into a stock that has just posted a 45% monthly gain, yet the borrow market remains…
TG Therapeutics arrives at its June 11 earnings call having surged 18% on the week to $43.37 — yet the short position that bears rebuilt through late May is essentially unchanged, leaving a loaded confrontation between…
TG Therapeutics heads into its June 11 earnings call in a starkly different place than it was a week ago — the stock has ripped 18% higher to $43.37 while a large short position remains firmly in place, setting up a…
TG Therapeutics enters its June 11 earnings call with a notable reversal underway — the short-covering trend that defined May has stalled, bears are rebuilding positions, and the stock has given back nearly 8% on the…
TG Therapeutics heads into its June 11 earnings call in a notably different posture than it entered May — short sellers are quietly covering, options traders have swung decisively bullish, and the stock is up more than…
TG Therapeutics reported Q1 2026 results today with a notable split: revenue of $204.9 million beat the $196.8 million consensus estimate, while adjusted EPS of $0.18 missed the $0.30 estimate by a wide margin. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TGTX — free to start on ORTEX.
Sign up for free →Open TGTX on ORTEX